NCT02508441终止1 期
A Phase 1 Open-label First-in-human Dose-escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available
Andes Biotechnologies1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2015年12月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Incidence of dose-limiting toxicities
研究概览
简要总结
This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors that are refractory to standard therapy or for which no standard therapy is available.
详细描述
Part 1 is a dose-escalation study to establish the maximum tolerated dose based on dose-limiting toxicities and to evaluate the safety and tolerability of multiple doses of Andes-1537 for Injection in patients with advanced unresectable solid tumors that are refractory to standard therapy or for which no standard therapy is available. Part 2 is an open-label, dose-expansion study to determine the safety, tolerability, and preliminary efficacy of Andes-1537 in patients with advanced solid tumors. In part 2, patients will be enrolled and receive the recommended phase 2 dose established in part 1 based on the safety, tolerability, pharmacokinetics, and preliminary efficacy data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women 18 years of age or older
- •Can understand and voluntarily sign an informed consent form prior to any study-related assessments or procedures, and are able to adhere to the study visit schedule and other protocol requirements
- •Patient with documented pathological evidence of a cancer from which has developed advanced unresectable solid tumors that are, in the opinion of their treating physician, refractory to standard therapy or for which no standard therapy is available
- •Consent to tumor biopsy from accessible tissue (optional in Part 1 and mandatory in Part 2)
- •Have measureable disease by RECIST
- •Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- •Have adequate organ function, confirmed by the following laboratory values obtained ≤ 3 days prior to the first treatment: absolute neutrophil count ≥ 1.5 × 10^9/L; hemoglobin ≥ 9 g/dL; platelets ≥ 100 × 10^9/L; aspartate transaminase and alanine transaminase ≤ 2.5 × upper limit of normal (ULN); serum total bilirubin ≤ 2.0 × ULN; serum creatinine ≤ 1.5 × ULN, or estimated or measured creatinine clearance ≥ 60 mL/min; prothrombin time, activated partial thromboplastin time ≤ 1.5 × ULN if not on anticoagulation therapy
- •Female patients of childbearing potential must have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug.
- •Male patients at screening must agree to practice adequate contraception from study entry through at least 6 months after discontinuation of study drug.
排除标准
- •Have symptomatic central nervous system metastases. Patients with brain metastases that have been previously treated and are stable for ≥ 4 weeks or treated with gamma knife surgery and are stable for ≥ 2 weeks are allowed to enter the study.
- •Have unstable angina, clinically significant cardiac arrhythmia, New York Heart Association Class 3 or 4 congestive heart failure, or prolonged QT interval corrected wave of greater than 470 ms.
- •Receiving treatment with any medication known to produce QT prolongation within 7 days of study entry
- •Have had prior systemic chemotherapy treatments or investigational modalities ≤ 5 half-lives or 4 weeks, whichever is shorter, prior to starting treatment with Andes-1537 or who have not recovered from side effects, grade 2 or greater, of such therapy (except alopecia)
- •Have had major surgery ≤ 2 weeks prior to starting treatment with Andes-1537 or who have not recovered from side effects of such surgery
- •Are pregnant or breastfeeding
- •Have had DVT or venous thromboembolism within 6 weeks of study entry
- •Have active uncontrolled bleeding or a known bleeding disorder
- •Have any serious or unstable concomitant systemic conditions that are incompatible with this clinical study, including but not limited to substance abuse, psychiatric disturbance, or uncontrolled intercurrent illness (including active infection), arterial thrombosis, or symptomatic pulmonary embolism
- •Have a known sensitivity to any of the components of Andes-1537
- •Are unable or unwilling to follow protocol instructions and requirements
研究组 & 干预措施
Andes-1537 for Injection
Experimental
Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
干预措施: Andes-1537 for Injection (Drug)
结局指标
主要结局
Incidence of dose-limiting toxicities
时间窗: First 4-week treatment cycle
Determine maximum tolerated dose
次要结局
- Adverse events(Safety evaluations will be measured through 28 days after last dose of Andes-1537)
- Physical examinations(Safety evaluations will be measured through 28 days after last dose of Andes-1537)
- Vital signs(Safety evaluations will be measured through 28 days after last dose of Andes-1537)
- 12-lead electrocardiogram (ECG)(First 4-week treatment cycle)
- Injection site reactions(Safety evaluations will be measured through 28 days after last dose of Andes-1537)
- Pharmacokinetic parameters in Andes-1537 in blood and urine for single-dose and multiple-dose evaluation(Pre-treatment, following first dose and last dose of cycle 1 (4-week cycle), first dose of each additional cycle through study completion, and last visit)
- Pharmacodynamic parameters in blood and biopsy samples from accessible tissue(Pre-treatment and at 4 and 8 weeks for biopsy; blood samples at pre-treatment, every 8 weeks, and last visit)
- Objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) with CT or MRI scan(Every 8 weeks following completion of 2 treatment cycles to cover from date of initiation until date of first documented progression or toxicity to Andes-1537, which ever comes first)
- Safety laboratory tests(Safety evaluations will be measured through 28 days after last dose of Andes-1537)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of BAY1834942 in Patients With Solid TumorsAdvanced CEACAM6-expressing Solid TumorsNCT03596372Bayer30
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid TumorsNCT06031441Genentech, Inc.65
已完成
1 期
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsSolid Tumor, AdultOvarian Serous AdenocarcinomaBiliary Cancer MetastaticOvarian Serous CystadenocarcinomaPancreatic Ductal AdenocarcinomaNCT05074472ZielBio, Inc.35
终止
1 期
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic SyndromesBlastic Plasmacytoid Dendritic Cell NeoplasiaNCT05086315Sanofi101
Unknown
1 期
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT05118841Nanjing Zenshine Pharmaceuticals60